Based on prioritization analyses using comparative genomics, we focused on Arhgap5 and Mecom. Transposon insertions appeared to inactivate these two genes (Fig. 6c) and termination mutations were observed in human CRC (Fig. 6d), suggesting that these genes could function as tumor suppressors. The gene discussed is MECOM; the disease is neoplasm.